Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?

Author(s): Marlana Orloff, Ryan Weight, Matias E. Valsecchi, Takami Sato

Journal Name: Reviews on Recent Clinical Trials

Volume 11 , Issue 2 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The combination of immune checkpoint inhibitors ipilimumab and nivolumab has been recently been FDA approved for first line treatment of unresectable and metastatic BRAF wild type melanoma. The approval came following the impressive results of the CheckMate 067, where the combination of ipilimumab and nivolumab appeared to outperform each as a single agent in regards to response rate and progression free survival. Though we await final overall survival data, the combination will likely be adapted by many oncologists and integrated into the ever changing melanoma treatment algorithm. In this article we aim to summarize the data leading up to the recent FDA approval and publication by Larkin et al. that presents the results from the CheckMate 067 trial. We will also further explore the feasibility, challenges, and applicability of combination immune checkpoint inhibitor therapy.

Keywords: Anti-CTLA-4, anti-PD-1, ipilimumab, melanoma, nivolumab.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [81 - 86]
Pages: 6
DOI: 10.2174/1574887111666160330120712
Price: $65

Article Metrics

PDF: 80